Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors
Author:
Affiliation:
1. Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2. Department of Ophthalmology, Shengli Oilfield Central Hospital, Dongying, Shan Dong Province, China
Publisher
Association for Research in Vision and Ophthalmology (ARVO)
Subject
General Medicine
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical Risk Factors for Retinopathy of Prematurity Reactivation after Intravitreal Antivascular Endothelial Growth Factor Injection;The Journal of Pediatrics;2024-10
2. Vascular development analysis: a study for tertiary anti-vascular endothelial growth factor therapy after second reactivation of retinopathy of prematurity;Frontiers in Medicine;2024-07-19
3. Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection;BMC Ophthalmology;2024-06-21
4. Prediction of Reactivation after Anti-VEGF Monotherapy for Retinopathy of Prematurity Using Multimodal Machine Learning models (Preprint);2024-05-11
5. Comparing reactivation and retreatment for three doses of bevacizumab in type 1 retinopathy of prematurity;Journal of American Association for Pediatric Ophthalmology and Strabismus;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3